

1 **Delayed generation of functional virus-specific circulating T**

2 **follicular helper cells correlates with severe COVID-19**

3

4 Meng Yu¹, Afandi Charles¹, Alberto Cagigi¹, Wanda Christ², Björn Österberg¹, Sara
5 Falck-Jones¹, Lida Azizmohammadi¹, Eric Åhlberg¹, Ryan Falck-Jones^{3,4}, Julia
6 Svensson¹, Mu Nie¹, Anna Warnqvist⁵, Fredrika Hellgren¹, Klara Lenart¹, Rodrigo
7 Arcoverde Cerveira¹, Sebastian Ols¹, Gustaf Lindgren¹, Ang Lin¹, Holden Maecker⁶,
8 Max Bell^{3,4}, Niclas Johansson^{7,8}, Jan Albert^{9,10}, Christopher Sundling^{7,8}, Paulo
9 Czarnewski¹¹, Jonas Klingström², Anna Färnert^{7,8}, Karin Loré¹ and Anna Smed-
10 Sörensen^{1*}

11

12

13 ¹Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet,
14 Karolinska University Hospital, Stockholm, Sweden. ²Department of Medicine Huddinge,
15 Karolinska Institutet, Stockholm, Sweden. ³Department of Physiology and Pharmacology,
16 Karolinska Institutet, Stockholm, Sweden. ⁴Department of Perioperative Medicine and Intensive
17 Care, Karolinska University Hospital, Stockholm, Sweden. ⁵Unit of Biostatistics, Institute of
18 Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ⁶The Human Immune
19 Monitoring Center, Institute of Immunity, Transplantation and Infection, Stanford University School
20 of Medicine, Stanford, California, USA. ⁷Division of Infectious Diseases, Department of Medicine
21 Solna, Center for Molecular Medicine, Karolinska Institutet, Sweden. ⁸Department of Infectious
22 Diseases, Karolinska University Hospital Solna, Stockholm, Sweden. ⁹Department of Microbiology,
23 Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. ¹⁰Clinical Microbiology,
24 Karolinska University Hospital Solna, Stockholm, Sweden. ¹¹Department of Biochemistry and
25 Biophysics, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Stockholm
26 University, Solna, Sweden.

27

28 **Correspondence to:** Anna Smed-Sörensen, Division of Immunology and Allergy,

29 Department of Medicine Solna, Karolinska Institutet, Visionsgatan 4, BioClinicum

30 J7:30, Karolinska University Hospital, 171 64 Stockholm, Sweden.

31 E-mail addresses: anna.smed.sorensen@ki.se

32

33

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 **Abstract**

35 Effective humoral immune responses require well-orchestrated cellular interactions
36 between B and T follicular helper (Tfh) cells. Whether this interaction is impaired and
37 associated with COVID-19 disease severity is unknown. Here, longitudinal acute and
38 convalescent blood samples from 49 COVID-19 patients across mild to severe
39 disease were analysed. We found that during acute infection activated and SARS-
40 CoV-2-specific circulating Tfh (cTfh) cell frequencies expanded with increasing
41 disease severity. The frequency of activated and SARS-CoV-2-specific cTfh cells
42 correlated with plasmablast frequencies and SARS-CoV-2 antibody titers, avidity and
43 neutralization. Furthermore, cTfh cells but not other memory CD4 T cells, isolated
44 from severe patients induced more pronounced differentiation of autologous
45 plasmablast and antibody production *in vitro* compared to cTfh cells isolated from
46 mild patients. However, the development of virus-specific cTfh cells was delayed in
47 patients that displayed or later developed severe disease compared to those that
48 maintained a mild or moderate disease. This correlated with a delayed induction of
49 high-avidity and neutralizing virus-specific antibodies. Our study therefore suggests
50 that impaired generation of functional virus-specific cTfh cells delays the production
51 of high-quality antibodies to combat the infection at an early stage and thereby
52 enabling progression to more severe COVID-19 disease.

53

54 **Introduction**

55 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes
56 coronavirus disease 2019 (COVID-19) with a broad spectrum of clinical outcome
57 ranging from asymptomatic to severe disease including life-threatening respiratory
58 failure, and even fatal outcome ^{1,2}. While immunopathology is clearly a driver of
59 COVID-19, knowledge about how immunological differences may dictate disease
60 severity is still incomplete ³. Understanding the nature of longitudinal immune
61 responses in COVID-19 patients could aid in understanding and even predicting
62 disease severity, as well as identifying therapeutics and more effective vaccines.

63

64 SARS-CoV-2-specific T and B cells as well as antibodies are detectable in COVID-
65 19 patients during acute infection across disease severity from asymptomatic to
66 severe outcome ⁴, and the levels are directly proportional to disease severity level
67 ^{5,6}. T follicular helper (Tfh) cells play a crucial role in orchestrating humoral immunity
68 by supporting B cell activation and antibody generation ⁷⁻¹⁰. In human secondary
69 lymphoid tissues, Tfh cells upregulate expression of the chemokine receptor CXCR5,
70 allowing for the localisation of Tfh cells to the germinal centres (GCs). There, Tfh
71 cells provide help to B cells via inducible costimulatory molecule (ICOS), CD40L and
72 IL-21, to facilitate class switch recombination, somatic hypermutation to form high-
73 affinity antibodies, and finally the generation of long-lived antibody-secreting B cells
74 ¹¹. In fatal COVID-19 patients, GCs were absent in spleen and lymph nodes and this
75 was associated with impaired Tfh cell differentiation ^{12,13}, indicating that loss of Tfh
76 cells might lead to fatal outcome in COVID-19 patients. But what role Tfh cells play in
77 non-fatal COVID-19 patients is still unclear since obtaining longitudinal lymph node
78 samples for research is typically not feasible during ongoing infection.

79

80 Instead, a CXCR5+ subset of CD4+ memory T cells, named circulating Tfh (cTfh),
81 has been identified in human peripheral blood, which shares phenotypic and
82 functional properties of *bona fide* Tfh cells ^{14,15}. Studies have shown that human cTfh
83 cells originate from lymph nodes and traffic into blood via the thoracic duct ^{16,17}. In
84 ICOS-deficient or CD40L-deficient patients, the formation of GCs is severely
85 impaired and consequently the numbers of cTfh cells is significantly reduced, further
86 supporting the hypothesis that cTfh cells are GC-derived ¹⁸. Human cTfh cells can be
87 divided into cTfh1 (CXCR3+CCR6-), cTfh2 (CXCR3-CCR6-) and cTfh17 (CXCR3-
88 CCR6+). cTfh1, cTfh2 and cTfh17 cells share the signature transcription factors and
89 cytokines of Th1 (IFN γ and T-bet), Th2 (IL-4, IL-5, IL-13 and GATA-3) and Th17 (IL-
90 17, IL-22 and ROR γ t) cells, respectively ¹⁹⁻²². *In vitro* studies have shown that
91 human cTfh1 cells sufficiently support only memory B cell differentiation, while cTfh2
92 and cTfh17 cells can activate naïve B cells ^{22,23}. Thus, cTfh cells could be considered
93 a surrogate of lymphoid Tfh cells.

94

95 Studies focused on COVID-19 convalescent individuals show presence of SARS-
96 CoV-2 specific cTfh cells that correlate with SARS-CoV-2 neutralizing antibody titers
97 ²⁴⁻²⁶. However, data on cTfh cells during acute SARS-CoV-2 infection across disease
98 severity is very limited. Thevarajan *et al.* reported that the frequency of ICOS+PD-1+
99 cTfh cells increased during acute infection in COVID-19 patients compared to
100 convalescent or healthy donors ^{27,28}. Increased expression of CXCR5 and ICOS on
101 SARS-CoV-2-specific CD4 T cells in mild to severe COVID-19 patients with acute
102 infection has been reported, but none of the studies tested cTfh functionality directly
103 ^{4,29}. Longitudinal, functional data on cTfh cells in COVID-19 patients across disease

104 severity from acute infection to convalescence is still missing and whether cTfh cell
105 frequency and function correlate with or even predict COVID-19 disease severity is
106 still unclear. Here, we investigated the characteristics of cTfh cells in COVID-19
107 patients across mild to severe disease, longitudinally from acute infection to 3 and 8
108 months convalescence and compared the functionality of cTfh cells from acute
109 COVID-19 patients across disease severity.

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129 **Results**

130 **Longitudinal sampling during SARS-CoV-2 infection**

131 In total, 49 adults with PCR-confirmed SARS-CoV-2 infection were enrolled in the
132 study. Longitudinal blood samples were collected multiple times during acute,
133 symptomatic disease as well as during convalescence (median 3 and 8 months from
134 symptom onset) (Figure 1a and b). Identical samples from 20 age- and gender-
135 matched pre-pandemic healthy controls (HCs) were used as baseline comparison
136 (Figure 1a and Table 1). Disease severity was assessed daily in admitted patients
137 and classified according to the respiratory domain of the sequential organ failure
138 assessment (SOFA) score, with additional levels for non-admitted patients as mild
139 cases. Patients were grouped based on their peak disease severity, which may differ
140 from disease severity at time of sampling (Figure 1b). In this study, patients with
141 mild, moderate and severe peak COVID-19 disease severity are hereafter referred to
142 as mild, moderate and severe patients. Medical records from patient groups across
143 disease severity were analysed (Table 2). The distribution of age varied significantly
144 across peak disease severity groups of COVID-19 patients ($P<0.05$), as did male
145 sex ($P<0.01$) and the BMI ($P<0.01$) (Table 2), similar to what has been observed in
146 other COVID-19 patient cohorts ^{1,30}.

147

148 **cTfh cell abundance and activation are altered in severe COVID-19**

149 To understand the longitudinal dynamics of cTfh cell characteristics in COVID-19
150 patients across disease severity, from acute disease to convalescence, PBMCs from
151 41 patients and 20 healthy controls were analysed by flow cytometry (Supplementary
152 Table 1). cTfh cells were identified as CXCR5+ memory CD4+ T cells and cTfh cell
153 activation was determined by expression of CD38 and ICOS ¹⁶ (Figure 1c). cTfh cells

154 were further differentiated based on CCR6 and CXCR3 expression to identify cTfh1
155 (CXCR3+, CCR6-), cTfh2 (CXCR3-, CCR6-) and cTfh17 (CXCR3-, CCR6+) cells
156 (Figure 1c). Total cTfh cell frequencies were significantly lower in moderate and
157 severe patients compared to mild during acute disease but normalized to similar
158 levels as observed in healthy controls (dotted line) during convalescence (Figure 1d).
159 During acute disease, frequencies of cTfh1 and cTfh17 but not cTfh2 cells were
160 significantly lower in severe patients than in mild patients, while there was no
161 significant difference in frequency of cTfh1, cTfh2 and cTfh17 cells in patients across
162 disease severity at the 3 and 8 months convalescence time points (Figure 1d). In
163 contrast, frequencies of activated CD38+ ICOS+ cTfh cells were significantly higher
164 in severe and moderate patients than in mild patients during acute disease and
165 normalised during both 3 and 8 months convalescence (Figure 1d). When looking at
166 cTfh subsets, there was no statistically significant differences in the frequency of
167 activated cTfh1, cTfh2 or cTfh17 cells during acute disease (Figure 1d). These
168 results show that as disease severity increased during acute SARS-CoV-2 infection,
169 cTfh cells were lower in frequency but a higher proportion were activated, suggesting
170 that cTfh cell frequency and activation associate with disease severity in COVID-19
171 patients during acute disease.

172

173 **Frequencies of activated cTfh cells correlate with SARS-CoV-2 plasma**
174 **antibody level and blood plasmablast frequencies in patients during acute**
175 **COVID-19**

176 To assess whether cTfh cell patterns associate with the humoral immune response,
177 longitudinal plasma antibody levels against SARS-CoV-2 spike and RBD by ELISA
178 as well as the blood plasmablast (PB) frequency were analyzed by flow cytometry

179 (Supplementary Figure 1 and Supplementary Table 2). In line with previous reports
180 from us and others³¹⁻³³, we found that plasma IgA and IgG against SARS-CoV-2
181 spike and RBD proteins increased with increasing disease severity, during both
182 acute disease and 3 months convalescence (Figure 2a). Furthermore, plasma IgA
183 against SARS-CoV-2 RBD and plasma IgG against SARS-CoV-2 spike and RBD
184 positively correlated with the frequency of activated cTfh cells during acute disease
185 (Figure 2b). Frequencies of activated cTfh1, cTfh2 and cTfh17 cells positively
186 correlated with plasma spike and RBD IgG, and frequencies of activated cTfh1 and
187 cTfh17 cells positively correlated with plasma RBD IgA (Figure 2c). Frequencies of
188 blood plasmablast in severe and moderate COVID-19 patients were significantly
189 higher than that in mild patients during acute disease and normalised to frequencies
190 comparable to healthy controls during convalescence (Figure 2d). During acute
191 disease, frequencies of blood plasmablast in patients across disease severity
192 positively correlated with the frequency of activated cTfh cells in the same samples
193 (Figure 2e), including cTfh1, cTfh2 and cTfh17 cells (Figure 2f).

194

195 **SARS-CoV-2 spike- and RBD-specific cTfh cell activation correlate with plasma**
196 **antibody levels and blood plasmablast frequencies during acute COVID-19**

197 Next, to mechanistically test whether cTfh cells are indeed reactive to SARS-CoV-2
198 antigens, we next measured the frequency of SARS-CoV-2 spike and RBD-specific
199 cTfh cells in patients across disease severity from acute infection to convalescence.
200 PBMCs from 41 patients or 20 healthy controls were stimulated with SARS-CoV-2
201 spike or RBD proteins, or with BSA or SEB as negative and positive controls,
202 respectively. After 20 hours of stimulation, cTfh cells from COVID-19 patients but not
203 cTfh cells from pre-pandemic healthy controls upregulated the activation markers

204 CD25 and CD134 in response to the viral proteins (Figure 3a and Supplementary
205 Table 3). We found that the frequencies of both spike- and RBD-specific cTfh cells
206 were significantly higher in severe and moderate patients than that in mild patients
207 during acute infection (Figure 3b). This pattern held true also during convalescence;
208 both spike- and RBD-specific cTfh cells were detectable in blood of former COVID-
209 19 patients, albeit at lower levels than during acute illness (Figure 3b), consistent
210 with previous studies²⁴⁻²⁶. Again, individuals who recovered from severe COVID-19
211 displayed higher frequencies of spike and RBD-specific cTfh cells even at 8 months
212 of convalescence compared to patients who had recovered from mild disease
213 (Figure 3b). Frequencies of spike and RBD-specific cTfh cells positively correlated
214 with frequencies of activated cTfh cells during acute infection (Supplementary Figure
215 2), indicating that the frequency of activated cTfh cells may reflect ongoing immune
216 reactions against the antigen or virus. During acute disease, the frequencies of
217 spike- and RBD-specific cTfh cells positively correlated with both plasma antibody
218 levels to the same viral proteins (Figure 3c) as well as to the blood plasmablast
219 frequency (Figure 3d). Cytokines produced by PBMCs in response to spike and RBD
220 were measured by Luminex, including IL-21, IFN γ , IL-4 and IL-17 (Figure 3e).
221 Furthermore, PBMCs isolated from severe COVID-19 patients at the acute phase of
222 disease produced higher levels of IL-21, IFN γ , IL-4 and IL-17 in response to spike
223 and RBD, than PBMCs from mild patients (Figure 3e). We also found the level of
224 plasma CXCL13 from severe COVID-19 patients was significantly higher than mild
225 patients during acute infection (Supplementary Figure 3). In addition, we found that
226 the frequencies of activated and virus-specific cTfh cells in COVID-19 patients with
227 acute disease were positively correlated with clinical parameters including age, CCI
228 and peak disease severity (Figure 3f). These data suggest that severe COVID-19

229 patients display a more robust cTfh cell response with higher level of activation
230 markers expression and cytokines production than mild COVID-19 patients in
231 response to SARS-CoV-2 protein, which was associated with higher frequencies of
232 blood antibody secreting cells and antibody titers against SARS-CoV-2 virus in
233 severe COVID-19 patients compared to mild patients. Plasma cytokines and
234 chemokines of COVID-19 patients with acute disease were analysed using a
235 proximity extension assay (Olink Proteomics) (Figure 3g). Furthermore, we found
236 that that frequencies of activated cTfh especially cTfh1 and cTfh2 cells, and
237 frequencies of virus-specific cTfh cells were positively correlated with acute disease
238 plasma levels of TNF protein family members including TNFRSF9, TNF β , TRAIL and
239 TWEAK, but negatively correlated with IL-6 (Figure 3g). Our data suggest that
240 cytokines responses induced by SARS-CoV-2 might affect generation of functional
241 virus-specific cTfh cells against COVID-19.

242

243 **cTfh cells isolated from severe COVID-19 patients support plasmablast**
244 **differentiation and antibody production *in vitro* more effectively than cTfh cells**
245 **from mild patients**

246 To confirm the functional capacity of cTfh cells from COVID-19 patients to help B cell
247 differentiation and antibody production, and compare the functional cTfh cell capacity
248 in severe and mild COVID-19 patients, we isolated cTfh and non-cTfh (CD3⁺ CD4⁺
249 CD45RA⁻ CXCR5⁻) cells from 4 severe and mild COVID-19 patient samples from the
250 acute stage of disease as well as from 4 healthy controls (Supplementary Table 4
251 and 5). cTfh and non-cTfh cells were co-cultured with autologous memory or naïve
252 B cells, respectively at a T cell: B cell ratio of 1:1, in the presence of Staphylococcal
253 enterotoxin B (SEB) to enhance the T-B cell interaction (Supplementary figure 4 and

254 Figure 4a). After 6 days co-culture of memory B cells and after 9 days co-culture of
255 naïve B cells with either cTfh or non-cTfh cells, the number of live B cells (Figure 4b-
256 c) as well as the frequency of differentiated CD38⁺ CD27⁺ plasmablasts (Figure 4d)
257 in the co-cultures was determined by flow cytometry. cTfh cells, but not non-cTfh
258 cells, efficiently supported both memory and naïve B cell survival and differentiation
259 into plasmablasts (Figure 4b-c). Importantly, cTfh cells isolated from severe COVID-
260 19 patients more efficiently supported memory and naïve B cell survival as well as
261 plasmablast differentiation, as compared to cTfh cells isolated from mild COVID-19
262 patients or from healthy controls (Figure 4c-d). Next, the concentration of total IgA
263 and IgG in the co-culture supernatants was measured by ELISA. (Figure 4e) IgA and
264 (Figure 4f) IgG were detectable in cTfh co-cultures with both memory B cells and
265 naïve B cells and immunoglobulin concentrations were significantly higher in co-
266 cultures with cells isolated from severe COVID-19 patients compared to mild patients
267 or healthy controls. In contrast, IgA or IgG were not detectable in supernatants from
268 non-cTfh cell co-cultures (Figure 4e-f). In line with cTfh cell functionality, IL-21 was
269 only detectable in cTfh co-cultures (Figure 4g). Again, IL-21 supernatant
270 concentrations were higher in co-cultures with cells isolated from severe COVID-19
271 patients compared to mild patients or healthy controls (Figure 4g), suggesting that
272 the functionality of overall cTfh cells is more potent in severe compared to mild
273 COVID-19.

274

275 **Appearance of SARS-CoV-2-specific cTfh cells is delayed in severe COVID-19** 276 **patients compared to patients with mild and moderate disease**

277 It is counter-intuitive that individuals with the highest frequencies and most functional
278 cTfh cells as well as the highest antibody levels directed to the virus are the most

279 severely ill patients. To resolve this paradox, we next took advantage of the fact that
280 we had longitudinal samples during acute disease after less than two weeks of
281 symptom onset, 2-3 weeks, 3-4 weeks as well as more than 4 weeks after symptom
282 onset in the different disease severity groups (Supplementary Figure 5). We found
283 that very early after symptom onset (< 2 weeks), in individuals who already displayed
284 or later developed severe disease, not only the frequencies of total cTfh cells (Figure
285 5a), but also the frequency of activated cTfh cells (Figure 5b) and importantly the
286 frequencies of spike- and RBD-specific cTfh cells (Figure 5c) were significantly lower
287 than in individuals who maintained/developed mild or moderate COVID-19. As the
288 disease progressed, severe patients presented with increased frequencies of
289 activated cTfh cells (Figure 5b) and SARS-CoV-2 spike- and RBD-specific (Figure
290 5c) cTfh cells to similar or higher levels than observed in mild and moderate patients
291 after 4 weeks after symptom onset. These data indicate that appearance of activated
292 and SARS-CoV-2-specific cTfh cells was delayed in severe patients compared to
293 moderate and mild patients during acute disease, potentially pointing to impaired
294 generation of virus-specific cTfh cells early during infection. However, there was no
295 significant difference in frequencies of SARS-CoV-2 spike- and RBD-specific
296 CXCR5- memory CD4 T cells (non-cTfh cells) between severe and mild COVID-19
297 patients during early infection (Figure 5d), suggesting that the delayed appearance
298 of virus-specific memory CD4 T cells was restricted to the cTfh cell compartment.
299 During early infection less than 2 weeks after symptom onset, frequencies of
300 activated non-cTfh cells were even higher in severe patients than in individuals who
301 maintained/developed mild or moderate COVID-19 (Figure 5e). We also found that
302 the severe COVID-19 patients with delayed generation of activated and virus-specific

303 cTfh cells, showed no significant difference in age, gender or CCI, but higher BMI
304 compared with mild and moderate patients (Table 3).

305

306 **Delayed appearance of virus-specific cTfh cells is associated with delayed**
307 **generation of high avidity and neutralizing plasma SARS-CoV-2 antibodies**

308 To understand the potential functional consequences of delayed appearance of
309 activated and virus-specific cTfh cells, we assessed the avidity and neutralizing
310 capacity of plasma antibodies against SARS-CoV-2 from COVID-19 patients during
311 acute disease. In line with the cTfh data, we found that in individuals who already
312 displayed or later developed severe disease, the avidity index of plasma IgG
313 antibodies against spike protein (Figure 5f and Supplementary Figure 6a) and the
314 plasma neutralization IC₁₀₀ against SARS-CoV-2 (isolate SARS-CoV-
315 2/human/SWE/01/2020) (Figure 5h) were significantly lower than in patients who
316 maintained or developed mild or moderate COVID-19 within 2 weeks after symptom
317 onset. However, the antibody avidity index and neutralizing capacity increased as
318 disease progressed and reached similar or higher levels than moderate patients after
319 4 weeks of symptom onset (Figure 5f, h and Supplementary Figure 6b). The
320 frequency of activated and SARS-CoV-2 spike-specific cTfh cells correlated strongly
321 with the avidity index of plasma IgG antibodies (Figure 5g) and plasma neutralization
322 IC₁₀₀ (Figure 5i). Though the titers of plasma IgA and IgG antibodies against SARS-
323 CoV-2 spike and RBD in severe patients showed similar or even higher level
324 compared with mild COVID-19 patients during early infection (Supplementary Figure
325 7a-b), the plasma neutralization potency (calculated as IC₁₀₀ divided by antibody
326 titers) in severe patients was significantly lower than mild and moderate patients
327 (Figure 5j). As failure to achieve high avidity and neutralizing antibodies has been

328 shown to result in a lack of protective immunity against SARS-CoV-2 infection ³⁴, our
329 study suggests that impaired generation of functional virus-specific cTfh cells delays
330 the production of protective antibodies to combat the infection at an early stage and
331 thereby enables progression to more severe COVID-19 disease. In summary,
332 delayed generation of activated and SARS-CoV-2-specific cTfh resulted in a delayed
333 production of high-quality antibodies for protection, which may consequently worsen
334 COVID-19 disease progression.

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351 **Discussion**

352

353 It is still unclear what immunological parameters may dictate the broad spectrum of
354 clinical outcomes after SARS-CoV-2 infection. Though several studies have reported
355 a positive relationship between disease severity and robust SARS-CoV-2 specific
356 antibody or T cell responses^{24,32,35}, how T cell and antibody responses affect
357 COVID-19 disease progress are still unclear. In this study, we focus on cTfh cells,
358 which originated from lymph nodes^{16,17} and display clonal and developmental
359 overlap with GC Tfh cells as supported by epigenetic, transcriptomic and TCR
360 repertoire studies^{16,36}. Thus, cTfh cells are considered a circulating counterpart of
361 *bona fide* lymphoid Tfh cells and a reflection of the GC reaction in response to
362 antigen^{23,37,38}. In SARS-CoV-2/COVID-19, studies on cTfh cells have focused on
363 convalescent individuals²⁴⁻²⁶ while longitudinal data on characteristics of cTfh cells
364 in COVID-19 patients during acute infection and the correlation with disease severity
365 have been missing. Whether cTfh cell functionality is impaired by viral infection, and
366 whether this connects with disease severity remains unclear. Here, we investigated
367 the characteristics and function of cTfh cells in COVID-19 patients with mild to
368 severe disease longitudinally during acute infection and convalescence in a clinically
369 well-characterized cohort.

370

371 In this study, we observed a delayed appearance of activated and SARS-CoV-2-
372 specific cTfh but not non-cTfh cells in severe compared to mild COVID-19 patients
373 during early infection (less than 2 weeks after symptom onset). Delayed generation
374 of high-avidity and neutralizing antibodies against SARS-CoV-2 were also observed
375 in severe compared to mild COVID-19 patients during the same period of early
376 infection, which strongly correlated with frequencies of both activated and virus-

377 specific cTfh cells, indicating that the delayed generation of activated and virus-
378 specific cTfh cells was associated with a delayed production of high quality of
379 productive antibodies. This may lead to reduced capacity to prevent viral spread at
380 early stages of infection and consequently may enable progression to more severe
381 COVID-19 disease. The delayed generation of functional virus-specific cTfh cells in
382 severe patients observed in our study may reflect the delayed germinal centre
383 reaction in severe compared with mild patients, which supports and potentially
384 explains the observation from other labs that patients with mild COVID-19 displayed
385 substantial affinity maturation for antibodies binding to the prefusion spike much
386 earlier than patients with severe COVID-19 ³⁹, and blunted affinity maturation against
387 the SARS-CoV-2 prefusion spike protein may predict worse outcome for hospitalized
388 patients ⁴⁰. We also found that at early infection, severe COVID-19 patients who had
389 a lower frequency of functional cTfh cells displayed similar or even higher plasma
390 antibody titers compared with mild patients, indicating the possibility of extrafollicular
391 antibody responses. However, these early Tfh-independent antibody responses in
392 severe patients were much lower in avidity and neutralizing capacity and
393 consequently less efficient in controlling viral spread which might contribute to
394 disease progression, compared with mild and moderate patients who displayed
395 higher frequencies of functional virus-specific cTfh cells during early infection.

396

397 The immunological reason for the impaired generation of cTfh cells could be a result
398 of complicated dysfunction of immune responses such as lymphopenia, aberrant
399 cytokine/chemokine production and dysregulated innate immune response in
400 COVID-19 patients with severe disease. Unfortunately, in the majority of our severe
401 and moderate patients, the count of lymphocytes was not tested at the same day

402 when the samples were collected for this study, thus we could not accurately assess
403 the absolute number of cTfh cells in blood or measure the impact of lymphopenia on
404 cTfh cells, which is a limitation of this study. But our Olink proteomics data show
405 frequencies of activated and virus-specific cTfh cells negatively correlated with IL-6
406 (Figure 3g). IL-6 has been considered a signal of a dysregulated cytokine response
407 contribute to severe COVID-19 outcome ⁴¹, suggesting the aberrant cytokine
408 response might be associated with impaired generation of cTfh cells. The Olink
409 proteomics data also suggest TNF family members, especially TNFRSF9, TNF β ,
410 TRAIL and TWEAK, positively correlate with activation of cTfh cells and generation
411 of virus-specific cTfh cells (Figure 3g). Interestingly, during the same period of early
412 infection when generation of functional virus-specific cTfh cells was impaired,
413 relatively lower levels of TNF β and TWEAK were also observed in patients who had
414 displayed or later developed severe COVID-19, compared with mild and moderate
415 patients, though differences were not statistically significant due to the limited
416 sample size (Supplementary figure 9). Studies have shown that the engagement of
417 ICOS on T cells by ICOS ligand (ICOS-L) on B cells is crucial for Tfh cell generation
418 ⁴². Non-canonical NF- κ B activation is considered an important factor for maintaining
419 high levels of ICOS-L expression in B cells, and consequently important for antigen-
420 stimulated Tfh cell differentiation ⁴³. While both TNF β and TWEAK have been
421 reported to induce the non-canonical NF- κ B pathway ⁴⁴, we could argue that low
422 levels of TNF β and TWEAK might be associated with impaired virus-specific cTfh
423 cell generation and activation in severe patients during early infection. This is
424 supported by another study showing that decreased expression of the costimulatory
425 molecule ICOS-L on B cells might impair Tfh cell activity in hospitalized compared
426 with ambulatory COVID-19 patients ⁴⁵. Altogether, our study provides some potential

427 clues that aberrant chemokine production might contribute to the delayed virus-
428 specific cTfh cell generation in severe patients during early infection period.

429

430 In addition, we found that characteristics of cTfh cells are associated with disease
431 severity in COVID-19 patients during acute infection. Our data show that severe
432 COVID-19 patients displayed the lowest frequency of total cTfh, cTfh1 and cTfh17
433 cells, in line with previous reports ^{46,47}. However, activated ICOS+CD38+ cTfh cells
434 dramatically increase in moderate and severe COVID-19 patients compared with
435 mild patients during acute disease, suggesting that activated cTfh cells may reflect
436 recent or ongoing virus encounter and emigration of cTfh cells from the GCs, similar
437 to observations from others ^{48,49}. This is in line with several studies trying to
438 understand the immune profile of COVID-19 patients ^{4,28,48} that report elevated
439 frequencies of CD38+ ICOS+ CXCR5+ CD4+ T cells during acute disease.
440 Importantly, we also found that the frequencies of SARS-CoV-2 spike- and RBD-
441 specific cTfh cells were higher in severe compared to mild patients. This was further
442 supported by cytokine data, showing that higher levels of typical cTfh cytokines were
443 secreted from PBMCs in response to SARS-CoV-2 spike and RBD proteins from
444 severe COVID-19 patients compared to mild patients. We also assessed the age,
445 gender and comorbidities previously demonstrated to be associated with disease
446 severity ^{1,30} and found that our severe patients were older and more frequently male
447 when compared with mild and moderate patients, similar to other reports ^{1,30}.
448 Interestingly, we found frequencies of activated and virus-specific cTfh cells
449 positively correlate with age and comorbidities, indicating that, along with other
450 clinical parameters, cTfh cells could be considered as a potential immunological
451 parameter that correlate with disease severity.

452

453 Furthermore, to compare the functionality of cTfh cells across COVID-19 disease
454 severity, we performed autologous cTfh-B cell co-cultures *in vitro*. We found that
455 cTfh cells but not non-cTfh cells from COVID-19 patients supported plasmablast
456 differentiation and antibody generation *in vitro*, and that the functionality of overall
457 cTfh cells from severe COVID-19 patients was even more potent than cTfh cells from
458 mild patients. One possible reason for this might be that cTfh cells isolated from
459 severe COVID-19 patients produce higher amounts of IL-21, a critical cytokine for B
460 cell differentiation and antibody production, compared to cTfh cells isolated from mild
461 patients. Blocking IL-21 would inhibit the generation of plasma cells *in vitro* ²³.
462 Another potential explanation for the superiority of cTfh cells from severe COVID-19
463 patients is that the frequency of activated ICOS+ cTfh cells is higher in severe
464 compared to mild patients (Supplementary Figure 7). ICOS, a member of the CD28
465 family of T-cell co-stimulators upregulated in activated T, facilitate T-B cell interaction
466 by binding to its ligand (ICOSL) expressed on B cells ^{50,51}. ICOS+ cTfh cells have
467 been reported to be more efficient in supporting B cell differentiation and antibody
468 production than ICOS- cTfh cells *in vitro* ²³. Due to the limited blood volume we were
469 able to obtain from each COVID-19 patient, it was not feasible to isolate sufficient
470 numbers of activated vs. non-activated cTfh cells, or SARS-CoV-2-specific vs. non-
471 specific cTfh cells for subsequent co-culture with autologous B cells, which is a
472 limitation of this study. Another limitation of this study is that virus-specific cTfh cells
473 function was not tested by adding viral proteins instead of superantigen partly due to
474 the limited cell numbers, as well as published data from the Ueno lab showing that
475 naïve B cells co-cultured with CXCR5+CD4+ T cells did not produce antibodies in
476 the absence of SEB ²².

477

478 In summary, we provide functional evidence that cTfh cells from COVID-19 patients
479 help antibody-secreting B cell differentiation and antibody generation, and that cTfh
480 cell characteristics are associated with disease severity. Generation of activated and
481 SARS-CoV-2-specific cTfh is delayed early during infection in patients who proceed
482 to develop severe COVID-19, resulting in a delayed production of high-quality
483 antibodies for protection that in turn might worsen disease progression. Our study
484 provides helps to understand the potential immunological factors associated with
485 disease severity in COVID-19 and suggests that identifying agents that could restore
486 impaired cTfh cell generation may be of therapeutic value in the future.

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516 **Methods**

517

518 **Study design and patient inclusion**

519 COVID-19 patients confirmed by SARS-CoV-2 PCR test were enrolled at the
520 Karolinska University Hospital and Haga Outpatient Clinic (Haga Närakut),
521 Stockholm, Sweden. Additionally, patients with mild disease were included by
522 recruiting household contacts who were SARS-CoV-2 PCR positive. In total 147
523 COVID-19 adult patients were recruited as previously reported^{33,52}. For this study,
524 we selected patients with non-fatal outcome and available biobanked longitudinal
525 acute and convalescent samples, and excluded patients with autoimmune disease or
526 haematological malignancies. Consequently, 41 COVID-19 patients were included in
527 this study. These patients were subsequently sampled at approximately 3 (n=39
528 patients) and 8 (n=35 patients) months after recovery. Blood samples from 20 age
529 and gender matched healthy controls (HCs) recruited prior to the pandemic were
530 also included (Figure 1a). Clinical characteristics were compared between the
531 COVID-19 patient cohort and HCs (Table 1). The total burden of comorbidities was
532 assessed using the Charlson Comorbidity index (CCI)⁵³. Disease severity was
533 assessed daily in admitted patients, according to the respiratory domain of the
534 sequential organ failure assessment (SOFA) score⁵⁴, with additional levels for non-
535 admitted patients as mild cases (Figure 1b). Patients were grouped depending on
536 their peak disease severity. Medical records from grouped patients across disease
537 severity were analysed (Table 2). We included the vast majority of our study
538 participants (9 mild, 14 moderate and 18 severe) in March-May 2020, when
539 corticosteroid use was still not common practice in Stockholm, Sweden. Therefore,
540 only 3 COVID-19 patients were treated with cortisone (Table 2), and one was
541 sampled before cortisone was administered. For functional co-culture experiments,

542 we recruited new patients (4 mild and 4 severe) in December 2020 – March 2021
543 that did not receive corticosteroid treatment during the sampling period. However,
544 two patients were sampled 26 and 37 days after corticosteroid treatment was
545 concluded. None of the patients in this study received IL-6 inhibitors (tocilizumab) or
546 IL-1 inhibitors during the study/sampling period.

547

548 **Flow cytometry**

549 Staining for subsets of cTfh cells and plasmablast in PBMCs was performed on
550 cryopreserved samples based on our earlier protocols^{55,56} with modifications. Cells
551 were stained using Live/Dead Blue (Invitrogen) or Live/Dead Aqua (Invitrogen) first
552 and then incubated with human FcR blocking reagent (Miltenyi Biotec) and stained
553 with appropriate combination of fluorescently labelled monoclonal antibodies
554 (Supplementary Table1-4) for 20 minutes at 4°C. Cells were washed with PBS and
555 fixed with 1% paraformaldehyde. Samples were acquired using LSRFortessa flow
556 cytometer (BD). Data were analysed using FlowJo version 10 (TreeStar).

557

558 **Cytokine and chemokine analysis**

559 Concentration of cytokines in the supernatants from PBMCs stimulation assay and
560 cTfh-B cell co-culture assay was determined by Custom-made Luminex® assay
561 (LXSAHM, R&D Systems), including IL-21, IFN γ , IL-4, IL-17 and TNF based on the
562 manufacturer's protocol. Briefly, supernatants were incubated with the microparticle
563 cocktail on a shaker (800 rpm) for 2 hours at room temperature (RT). Then wells
564 were washed and incubated with biotin-antibody cocktail on a shaker (800 rpm) for 1
565 hour at RT. Next wells were washed and incubated with Streptavidin-PE on a shaker

566 (800 rpm) for 0.5 hour at RT. Subsequently, wells were washed and diluted in wash
567 buffer and the results were generated by Bio-Plex 200 analyzer (BIO-RAD).

568

569 Plasma chemokine CXCL13 was analysed using aptamer-based SOMAscan[®]
570 proteomic discovery platform v4.1 (SOMALogic Inc., Boulder CO), according to the
571 manufacturer's protocols⁵⁷. The discovery platform allows detection of
572 approximately 7,000 protein analytes using modified single stranded DNA-based
573 protein affinity reagents referred as SOMAmers (Slow Off-rate Modified Aptamers).
574 The data generated from this assay passed through multiple standardization and
575 normalization steps including adaptive normalization by maximum likelihood to
576 minimize intra- and inter-assay variation. The quantitative levels of protein analytes
577 were presented as relative fluorescence unit (RFU). For this paper, only CXCL13
578 data were included.

579

580 Plasma cytokines and chemokines were also tested by Olink Proteomics assay (92-
581 biomarker Inflammation panel) performed based on the manufacturer's instructions
582⁵⁸. Briefly, DNA oligonucleotides labelled antibodies combine with target antigen and
583 oligonucleotides were hybridized and extended by DNA polymerase. Then protein
584 expression levels were determined by high-throughput real-time PCR and presented
585 as normalized protein expression (NPX) values. Values were calculated from
586 inverted Ct values, with a high NPX value corresponding to a high protein
587 concentration. Intensity normalization of data was performed according to the
588 manufacturer's protocol, to minimized intra- and interassay variation.

589

590 **Detection of SARS-CoV-2-specific cTfh cells**

591 Recombinant SARS-CoV-2 spike and receptor binding domain (RBD) proteins were
592 received through the global health-vaccine accelerator platforms (GH-VAP) funded
593 by the Bill & Melinda Gates Foundation. Cryopreserved PBMCs were thawed and
594 rested for 2h at incubator. Then cells were cultured in 96-well U-bottomed plates
595 (0.5×10^6 cells per well) and exposed to 5 $\mu\text{g}/\text{mL}$ of protein (SARS-CoV-2 spike,
596 SARS-CoV-2 RBD and BSA), or 5 $\mu\text{g}/\text{mL}$ of staphylococcal enterotoxin B (SEB) for
597 20 h. After stimulation, cells were collected and analysed by flow cytometry as
598 described above; culture supernatants were harvested to determine concentrations
599 of cytokines by Luminex® assay.

600

601 **Serology**

602 The titers of plasma IgA and IgG binding against SARS-CoV-2 spike trimer or
603 receptor binding domain (RBD) monomer were determined by enzyme-linked
604 immunosorbent assay (ELISA). Recombinant SARS-CoV-2 spike and RBD proteins
605 were received through the global health-vaccine accelerator platforms (GH-VAP)
606 funded by the Bill & Melinda Gates Foundation. Briefly, 96-half well plates were
607 coated with 50ng/well of the respective protein. Plates were incubated with duplicate
608 dilution (1:20) of each plasma sample at ambient temperature for 2 hours. Detection
609 was performed with a goat anti-human IgG HRP-conjugated secondary antibody
610 from BD Biosciences (Clone G18-145) followed by incubation with TMB substrate
611 (BioLegend) which was stopped with a 1M solution of H_2SO_4 . Absorbance was read
612 at 450nm + 550nm (background correction) using an ELISA reader. Data are
613 represented as the mean OD value of the 2 duplicates.

614

615 Plasma antibody avidity were tested for by an anti-SARS-CoV-2 ELISA ⁵⁵. Briefly,
616 96-half well plates were coated with 50ng/well of the recombinant SARS-CoV-2
617 spike protein. Plates were incubated with 5-fold dilution series of each plasma
618 sample at ambient temperature for 2 hours and then washed with 0.1% Tween-
619 20/PBS washing buffer. To determine the relative avidity index, two rows of
620 microplate wells next to each other were used for each subject. In one row wells
621 were incubated with PBS and in the other row wells were incubated with 1.5M
622 solution of sodium thiocyanate for 10 minutes at ambient temperature, followed by
623 washing with washing buffer. The sodium thiocyanate treatment leads to the
624 detachment of low-avidity antibodies from the antigen. Detection was performed with
625 a goat anti-human IgG HRP-conjugated secondary antibody from BD Biosciences
626 (Clone G18-145) followed by incubation with TMB substrate (BioLegend) which was
627 stopped with a 1M solution of H₂SO₄. Absorbance was read at 450nm + 570nm
628 (background correction) using an ELISA reader and the half maximal effective
629 concentration (EC₅₀) was calculated using GraphPad Prism 9. The relative avidity
630 index was calculated from the ratio of the EC₅₀ with and without sodium thiocyanate
631 treatment and is expressed as percentage.

632

633 Neutralization of replicating SARS-CoV-2 in plasma samples from COVID-19
634 patients was as described previously ^{59,60}. Briefly, plasma from COVID-19 patients
635 was 3-fold serially diluted, mixed with SARS-CoV-2 (isolate SARS-CoV-
636 2/human/SWE/01/2020, [https://www-ncbi-nlm-nih-
637 gov.proxy.kib.ki.se/nuccore/MT093571](https://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/nuccore/MT093571)), incubated for 1 hour and added, in
638 duplicates, to confluent Vero E6 cells in 96-well plates. After 5 days of incubation,
639 wells were inspected for signs of cytopathic effects (CPE) by optical microscopy.

640 Each well was scored as either neutralizing (if no signs of CPE was observed) or
641 non-neutralizing (if any CPE was observed). The arithmetic mean neutralization titer
642 of the reciprocals of the highest neutralizing dilutions from the two duplicates for
643 each sample was then calculated to determine the IC100.

644

645 **cTfh functional assay**

646 cTfh, non-cTfh, naïve and memory B cells were sorted from frozen PBMCs from
647 three severe and mild COVID-19 patients with acute disease respectively and three
648 healthy donors, using FACS Aria Fusion (BD) with a 100µm nozzle (Supplementary
649 figure 2 and Supplementary table). Sorted cTfh or non-cTfh cells (5×10^4 cells per
650 well) were co-cultured with autologous memory B cells (5×10^4 cells per well) for 6
651 days and with autologous naïve B cells (5×10^4 cells per well) for 9 days in complete
652 RPMI 1640 + 10% FCS in the presence of SEB (1µg/mL) in 96-well U-bottomed
653 plates. Culture supernatants were harvested at day 2 to measure cytokines by
654 Luminex® assay. After 6 and 9 days of culturing, cells were harvested to determine
655 B cell count and differentiation by flow cytometry as described above, and culture
656 supernatants were collected to test IgA and IgG concentrations by ELISA.

657

658 **Statistical analyses**

659 All statistical analyses were performed using RStudio (version 4.1.2), Prism 9
660 (GraphPad) and SPSS version 27.0 (IBM, New York). Grouped data are generally
661 presented as means unless otherwise specified. The estimating of all regression
662 models was done using Generalized Estimating Equations (GEE) to account for the
663 intra-person correlations inherent to repeated measures. An exchangeable
664 correlation structure was used. Adjusted estimates for average differences in the

665 different outcomes between groups were calculated with a linear model. Time-period
666 specific differences between groups were calculated by using time-period specific
667 subsets of the data. The graphical presentations of the different outcomes were
668 based on a GEE model with time modelled using a restricted cubic spline with knots
669 at 0, 14, 21, 28 and 53 days. For heatmaps, repeated measures correlations were
670 calculated, except for age, BMI, CCI, D-dimer and ferritin, which either had no time
671 specific variation (age, BMI, CCI) or too few values. For these variables the
672 correlations were calculated by collapsing the timepoints to one mean value/person.
673 In the presence of repeated measures, parametric correlation measures based on an
674 ANCOVA model was chosen, as there are no non-parametric correlation coefficients
675 for repeated measures. For the heatmaps, when there were no repeated measures,
676 Spearman rho was used. Data of all convalescent samples were performed using
677 the Kruskal-Wallis' test. For the clinical tables, data was presumed to have a non-
678 standard distribution and comparisons between continuous variables were
679 performed using the Mann-Whitney U-test or Kruskal-Wallis' test where appropriate.
680 In the case of using Kruskal-Wallis' test, multiple comparisons were performed using
681 Dunn's test. Nominal variables were compared between groups using Fisher's exact
682 test. Interdependence of two non-categorical parameters was performed using
683 Spearman's rho. A significance level of 95% was used and all tests were two-tailed.
684 In the case of using Spearman's rho when there were repeated samples, the data
685 from earliest sample was involved as representative for patients with longitudinal
686 acute samples.

687

688

689

690 **Study approval**

691 The study was approved by the Swedish Ethical Review Authority, and performed
692 according to the Declaration of Helsinki. Written informed consent was obtained from
693 all patients and controls. For sedated patients, the denoted primary contact was
694 contacted and asked about the presumed will of the patient and to give initial oral
695 and subsequently signed written consent. When applicable, retrospective written
696 consent was obtained from patients with non-fatal outcomes.

697
698 **Author contributions**

699
700 Experimental study design: M.Y., and A.S-S. Patient recruitment and sample
701 collecting: S. F-J., B.Ö., L.A., E.Å., R. F-J., M.B., N.K. and A.F. Anonymized patient
702 clinical data collection and interpretation: S. F-J., B.Ö., L.A., E.Å., R. F-J. and J.A.
703 Sample processing: M.Y., Af.C., Al.C., B.Ö., S. F-J., F.H., K.L., J.S., L.A. and E.Å.
704 Data generation: M.Y., Af.C., Al.C., W.C. and M.N. Analysis and interpretation of
705 data: M.Y., Af.C., Al.C., A.W., B.Ö., S. F-J., P.C., H.M., R.A.C., S.O., C.S., W.C.,
706 J.K., K.L., A.F. and A.S-S. Preparation of figures: M.Y. and Af.C. Creating schematic
707 illustrations: M.Y. and P.C. Manuscript writing: M.Y. and A.S-S. Critical revision of
708 the manuscript: all authors.

709

710 **Declaration of interests**

711 A.S-S. is a consultant for Astra Zeneca on studies unrelated to this research. All
712 other authors declare no conflict of interests.

713

714 **Acknowledgments**

715 We thank the patients and healthy volunteers who have contributed to this study. We
716 would also like to thank hospital staff for assistance with patient sampling, collection

717 of clinical data and sample processing. We also thank Neil King, Lauren Carter, and
718 members of the Institute for Protein Design Core Laboratories, University of
719 Washington, Seattle, WA, United States for recombinant protein reagents. We also
720 thank Tyson H. Holmes for the analysis of Olink data and revision of the manuscript.
721 We also thank Paulo Czarnewski for providing schematic illustrations. This work was
722 supported by grants from the Swedish Research Council, the Swedish Heart-Lung
723 Foundation, the Bill & Melinda Gates Foundation, the Knut and Alice Wallenberg
724 Foundation through SciLifeLab and Karolinska Institutet. Paulo Czarnewski is
725 financially supported by the Knut and Alice Wallenberg Foundation as part of the
726 National Bioinformatics Infrastructure Sweden at SciLifeLab.

727

728


729 References

- 730 1. Zhou, F., *et al.* Clinical course and risk factors for mortality of adult inpatients with
731 COVID-19 in Wuhan, China: a retrospective cohort study. *The lancet* **395**, 1054-1062
732 (2020).
- 733 2. Azkur, A.K., *et al.* Immune response to SARS-CoV-2 and mechanisms of
734 immunopathological changes in COVID-19. *Allergy* **75**, 1564-1581 (2020).
- 735 3. Brodin, P. Immune determinants of COVID-19 disease presentation and severity.
736 *Nature Medicine* **27**, 28-33 (2021).
- 737 4. Mathew, D., *et al.* Deep immune profiling of COVID-19 patients reveals distinct
738 immunotypes with therapeutic implications. *Science* **369**, eabc8511 (2020).
- 739 5. Bertoletti, A., Tan, A.T. & Le Bert, N. The T-cell response to SARS-CoV-2: kinetic and
740 quantitative aspects and the case for their protective role. *Oxford Open Immunology*
741 **2**, iqab006 (2021).
- 742 6. Sosa-Hernández, V.A., *et al.* B cell subsets as severity-associated signatures in COVID-
743 19 patients. *Frontiers in immunology*, 3244 (2020).
- 744 7. Song, W. & Craft, J. T follicular helper cell heterogeneity: time, space, and function.
745 *Immunological reviews* **288**, 85-96 (2019).
- 746 8. Liu, S.M. & King, C. IL-21-producing Th cells in immunity and autoimmunity. *The*
747 *Journal of Immunology* **191**, 3501-3506 (2013).
- 748 9. Gustafson, C.E., Weyand, C.M. & Goronzy, J.J. T follicular helper cell development
749 and functionality in immune ageing. *Clinical Science* **132**, 1925-1935 (2018).
- 750 10. Mudd, P.A., *et al.* SARS-CoV-2 mRNA vaccination elicits a robust and persistent T
751 follicular helper cell response in humans. *Cell* (2021).
- 752 11. Biram, A., Davidzohn, N. & Shulman, Z. T cell interactions with B cells during germinal
753 center formation, a three-step model. *Immunological reviews* **288**, 37-48 (2019).
- 754 12. Duan, Y.-q., *et al.* Deficiency of Tfh cells and germinal center in deceased COVID-19
755 patients. *Current medical science* **40**, 618-624 (2020).
- 756 13. Kaneko, N., *et al.* Loss of Bcl-6-expressing T follicular helper cells and germinal
757 centers in COVID-19. *Cell* **183**, 143-157. e113 (2020).
- 758 14. Ueno, H. Human circulating T follicular helper cell subsets in health and disease.
759 *Journal of clinical immunology* **36**, 34-39 (2016).
- 760 15. Schmitt, N., Bentebibel, S.-E. & Ueno, H. Phenotype and functions of memory Tfh
761 cells in human blood. *Trends in immunology* **35**, 436-442 (2014).
- 762 16. Vella, L.A., *et al.* T follicular helper cells in human efferent lymph retain lymphoid
763 characteristics. *The Journal of clinical investigation* **129**, 3185-3200 (2019).
- 764 17. Pahwa, S. Searching for the origin of the enigmatic circulating T follicular helper cells.
765 *The Journal of clinical investigation* **129**, 3048-3051 (2019).
- 766 18. Bossaller, L., *et al.* ICOS deficiency is associated with a severe reduction of CXCR5+
767 CD4 germinal center Th cells. *The Journal of Immunology* **177**, 4927-4932 (2006).
- 768 19. Deng, J., Wei, Y., Fonseca, V.R., Graca, L. & Yu, D. T follicular helper cells and T
769 follicular regulatory cells in rheumatic diseases. *Nature Reviews Rheumatology* **15**,
770 475-490 (2019).
- 771 20. Choi, J.Y., *et al.* Circulating follicular helper-like T cells in systemic lupus
772 erythematosus: association with disease activity. *Arthritis & rheumatology* **67**, 988-
773 999 (2015).


- 774 21. Huang, Q., Xu, L. & Ye, L. T cell immune response within B-cell follicles. *Advances in*
775 *immunology* **144**, 155-171 (2019).
- 776 22. Morita, R., *et al.* Human blood CXCR5+ CD4+ T cells are counterparts of T follicular
777 cells and contain specific subsets that differentially support antibody secretion.
778 *Immunity* **34**, 108-121 (2011).
- 779 23. Bentebibel, S., *et al.* Induction of ICOS CXCR3 CXCR5 TH cells correlates with
780 antibody responses to influenza vaccination. *Sci Transl Med* **5**: 176ra32. (2013).
- 781 24. Zhang, J., *et al.* Spike-specific circulating T follicular helper cell and cross-neutralizing
782 antibody responses in COVID-19-convalescent individuals. *Nature microbiology* **6**, 51-
783 58 (2021).
- 784 25. Boppana, S., *et al.* SARS-CoV-2-specific circulating T follicular helper cells correlate
785 with neutralizing antibodies and increase during early convalescence. *PLoS*
786 *Pathogens* **17**, e1009761 (2021).
- 787 26. Juno, J.A., *et al.* Humoral and circulating follicular helper T cell responses in
788 recovered patients with COVID-19. *Nature medicine* **26**, 1428-1434 (2020).
- 789 27. Thevarajan, I., *et al.* Breadth of concomitant immune responses prior to patient
790 recovery: a case report of non-severe COVID-19. *Nature medicine* **26**, 453-455
791 (2020).
- 792 28. Koutsakos, M., *et al.* Integrated immune dynamics define correlates of COVID-19
793 severity and antibody responses. *Cell Reports Medicine* **2**, 100208 (2021).
- 794 29. Lu, X., *et al.* Identification of conserved SARS-CoV-2 spike epitopes that expand
795 public cTfh clonotypes in mild COVID-19 patients. *Journal of Experimental Medicine*
796 **218**(2021).
- 797 30. Wang, D., *et al.* Correlation analysis between disease severity and clinical and
798 biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive
799 study. *BMC infectious diseases* **20**, 1-9 (2020).
- 800 31. Henss, L., *et al.* Analysis of humoral immune responses in patients with severe acute
801 respiratory syndrome coronavirus 2 infection. *The Journal of Infectious Diseases* **223**,
802 56-61 (2021).
- 803 32. Anichini, G., *et al.* Antibody response to SARS-CoV-2 in infected patients with
804 different clinical outcome. *Journal of Medical Virology* **93**, 2548-2552 (2021).
- 805 33. Cagigi, A., *et al.* Airway antibodies emerge according to COVID-19 severity and wane
806 rapidly but reappear after SARS-CoV-2 vaccination. *JCI insight* **6**(2021).
- 807 34. Bauer, G. The potential significance of high avidity immunoglobulin G (IgG) for
808 protective immunity towards SARS-CoV-2. *International journal of infectious diseases*
809 **106**, 61-64 (2021).
- 810 35. Peng, Y., *et al.* Broad and strong memory CD4+ and CD8+ T cells induced by SARS-
811 CoV-2 in UK convalescent individuals following COVID-19. *Nature immunology* **21**,
812 1336-1345 (2020).
- 813 36. Brenna, E., *et al.* CD4+ T follicular helper cells in human tonsils and blood are clonally
814 convergent but divergent from non-Tfh CD4+ cells. *Cell reports* **30**, 137-152. e135
815 (2020).
- 816 37. Koutsakos, M., *et al.* Circulating TFH cells, serological memory, and tissue
817 compartmentalization shape human influenza-specific B cell immunity. *Science*
818 *translational medicine* **10**, eaan8405 (2018).

- 819 38. Bentebibel, S., *et al.* ICOS (+) PD-1 (+) CXCR3 (+) T follicular helper cells contribute to
820 the generation of high-avidity antibodies following influenza vaccination. *Sci Rep* 6:
821 26494. (2016).
- 822 39. Ravichandran, S., *et al.* Longitudinal antibody repertoire in “mild” versus “severe”
823 COVID-19 patients reveals immune markers associated with disease severity and
824 resolution. *Science Advances* 7, eabf2467 (2021).
- 825 40. Tang, J., *et al.* Antibody affinity maturation and plasma IgA associate with clinical
826 outcome in hospitalized COVID-19 patients. *Nature communications* 12, 1-13 (2021).
- 827 41. Del Valle, D.M., *et al.* An inflammatory cytokine signature predicts COVID-19 severity
828 and survival. *Nature medicine* 26, 1636-1643 (2020).
- 829 42. Linterman, M.A. & Vinuesa, C.G. Signals that influence T follicular helper cell
830 differentiation and function. in *Seminars in immunopathology*, Vol. 32 183-196
831 (Springer, 2010).
- 832 43. Hu, H., *et al.* Noncanonical NF- κ B regulates inducible costimulator (ICOS) ligand
833 expression and T follicular helper cell development. *Proceedings of the National*
834 *Academy of Sciences* 108, 12827-12832 (2011).
- 835 44. Sun, S.-C. The non-canonical NF- κ B pathway in immunity and inflammation. *Nature*
836 *Reviews Immunology* 17, 545-558 (2017).
- 837 45. Hanson, A., *et al.* Impaired ICOS signaling between Tfh and B cells distinguishes
838 hospitalized from ambulatory CoViD-19 patients. *medRxiv* (2020).
- 839 46. Fenoglio, D., *et al.* Characterization of T lymphocytes in severe COVID-19 patients.
840 *Journal of medical virology* 93, 5608-5613 (2021).
- 841 47. Oja, A.E., *et al.* Divergent SARS-CoV-2-specific T- and B-cell responses in severe but
842 not mild COVID-19 patients. *European journal of immunology* 50, 1998-2012 (2020).
- 843 48. Zenarruzabeitia, O., *et al.* T cell activation, highly armed cytotoxic cells and a shift in
844 monocytes CD300 receptors expression is characteristic of patients with severe
845 COVID-19. *Frontiers in immunology* 12(2021).
- 846 49. Cui, D., *et al.* Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2
847 Infection. *Frontiers in Immunology*, 3806 (2021).
- 848 50. Panneton, V., Chang, J., Witalis, M., Li, J. & Suh, W.K. Inducible T-cell co-stimulator:
849 Signaling mechanisms in T follicular helper cells and beyond. *Immunological Reviews*
850 291, 91-103 (2019).
- 851 51. Wan, Z., Lin, Y., Zhao, Y. & Qi, H. TFH cells in bystander and cognate interactions with
852 B cells. *Immunological reviews* 288, 28-36 (2019).
- 853 52. Falck-Jones, S., *et al.* Functional monocytic myeloid-derived suppressor cells increase
854 in blood but not airways and predict COVID-19 severity. *The Journal of clinical*
855 *investigation* 131(2021).
- 856 53. Charlson, M.E., Pompei, P., Ales, K.L. & MacKenzie, C.R. A new method of classifying
857 prognostic comorbidity in longitudinal studies: development and validation. *Journal*
858 *of chronic diseases* 40, 373-383 (1987).
- 859 54. Vincent, J.-L., *et al.* The SOFA (Sepsis-related Organ Failure Assessment) score to
860 describe organ dysfunction/failure. (Springer-Verlag, 1996).
- 861 55. Lindgren, G., *et al.* Induction of robust B cell responses after influenza mRNA
862 vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+
863 CXCR3+ T follicular helper cells. *Frontiers in immunology* 8, 1539 (2017).
- 864 56. Lin, A., *et al.* Live attenuated pertussis vaccine BPZE1 induces a broad antibody
865 response in humans. *The Journal of clinical investigation* 130, 2332-2346 (2020).


- 866 57. Kim, C.H., *et al.* Stability and reproducibility of proteomic profiles measured with an
867 aptamer-based platform. *Scientific reports* **8**, 1-10 (2018).
- 868 58. Assarsson, E., *et al.* Homogenous 96-plex PEA immunoassay exhibiting high
869 sensitivity, specificity, and excellent scalability. *PloS one* **9**, e95192 (2014).
- 870 59. Kaku, C.I., *et al.* Broad anti-SARS-CoV-2 antibody immunity induced by heterologous
871 ChAdOx1/mRNA-1273 vaccination. *Science* **375**, 1041-1047 (2022).
- 872 60. Varnaité, R., *et al.* Expansion of SARS-CoV-2-specific antibody-secreting cells and
873 generation of neutralizing antibodies in hospitalized COVID-19 patients. *The Journal*
874 *of Immunology* **205**, 2437-2446 (2020).
- 875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915




Longitudinal frequency and activation of cTfh cells in COVID-19 patients across disease severity from acute disease up to 8 months convalescence. (a) Overview of study cohort (n=75), and (b) the timeline of longitudinal sampling. Patients are grouped based on peak disease severity, including mild (green), moderate (orange) and severe (red). Individual patients are color-coded based on daily disease severity. PaO₂ is expressed in kPa. (c) Gating strategy to identify cTfh cells in PBMCs by flow cytometry. From single, live CD3⁺ CD4⁺ T cells, memory CD4⁺ T cells were identified as CD45RA⁻. From memory CD4⁺ T cells, cTfh cells were identified as CXCR5⁺ cells. cTfh subsets were identified as cTfh1 (CXCR3⁺ CCR6⁻), cTfh2 (CXCR3⁻ CCR6⁻) and cTfh17 (CXCR3⁻ CCR6⁺). Activated cTfh and its subsets were identified with ICOS⁺ CD38⁺ expressing. Patients are grouped based on peak disease severity, including mild (green), moderate (orange) and severe (red). (d) Bar charts show the frequency of bulk and activated cTfh, cTfh1, cTfh2 and cTfh17 cells from COVID-19 patients with acute disease (Acute), 3 months convalescence (3 months) and 8 months convalescence (8 months) with median. Dots are individual samples color-coded according to peak disease severity. Dotted lines show the median frequency with 95% CI (grey area) of pre-pandemic healthy controls. X axis shows the number of patients in each bar. During acute disease, 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed and Generalized Estimating Equations (GEE) was used to account for the intra-person correlations inherent to repeated measures and assess statistically significant differences at p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. During 3 and 8 months convalescence, only 1 sample from each patient was analysed and Kruskal-Wallis with Dunn's multiple comparisons test was used to assess statistically significant differences at p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Figure 2


Longitudinal titers of plasma immunoglobulins against SARS-CoV-2 spike and RBD and frequency of blood plasmablast (PB) in COVID-19 patients across disease severity from acute disease up to 8 months convalescence. (a) Titers of plasma IgA and IgG against SARS-CoV-2 spike and RBD were tested by ELISA and bar charts show the OD value with median. During acute infection, 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed and Generalized Estimating Equations (GEE) was used to account for the intra-person correlations inherent to repeated measures and assess statistically significant differences at $p < 0.05$, $** p < 0.01$, $*** p < 0.001$, $**** p < 0.0001$. During 3 and 8 months convalescence, only 1 sample from each patient was analysed and Kruskal-Wallis with Dunn's multiple comparisons test was used to assess statistically significant differences at $p < 0.05$. $** p < 0.01$, $*** p < 0.001$, $**** p < 0.0001$. One severe patient displayed IgA deficiency over time was excluded in all IgA analysis. (b-c) Spearman correlation for plasma immunoglobulins against the spike and RBD versus frequency of (b) activated cTfh and (c) activated cTfh subsets during acute disease. 9, 14 and 18 individual samples from 9 mild, 14 moderate and 18 severe patients were analysed. For patients with longitudinal acute samples, data from the earliest sample was involved as representative in Spearman correlation analysis. (d) Frequency of plasmablast out of CD19+ B cells from COVID-19 patients is shown by bar charts with median, and the dotted lines show the median frequency with 95% CI (grey area) of healthy controls. Dots are individual samples color-coded according to peak disease severity. X axis shows the number of patients in each bar. Only 1 individual sample from each patient was analysed during both acute disease and convalescence. Kruskal-Wallis with Dunn's multiple comparisons test was used to consider all statistically significant at $p < 0.05$. $** p < 0.01$, $*** p < 0.001$, $**** p < 0.0001$. (e-f) Spearman correlation for frequency of plasmablast versus frequency of (e) activated cTfh and (f) activated cTfh subsets during acute disease. 9, 10 and 9 individual samples from 9 mild, 10 moderate and 9 severe patients were analysed so that only 1 individual sample from each patient was analysed during acute disease.



Longitudinal frequency of SARS-CoV-2 spike and RBD-specific cTfh in COVID-19 patients across disease severity from acute disease up to 8 months convalescence. PBMCs from COVID-19 patients or healthy controls were cultured and stimulated with 5 μ g/mL SARS-CoV-2 spike or RBD protein for 20 hours, then cells were tested by flow cytometry and cytokines in supernatant were determined by Luminex. Cells were also exposed to 5 μ g/mL BSA protein or 0.1 μ g/mL SEB as negative and positive controls respectively. (a) Representative example with gating strategy to identify SARS-CoV-2 spike and RBD-specific cTfh by flow cytometry. From single, live CD3⁺ CD4⁺ CD45RA⁻ CXCR5⁺ cTfh cells, CD25⁺ CD134⁺ cells were determined as virus-specific cTfh. (b) Bar charts show the median frequency of SARS-CoV-2 spike and RBD-specific cTfh from acute disease up to 8 months convalescence with median. Dots are individual samples color-coded according to peak disease severity. Dotted lines show the median frequency with 95% CI (grey area) of healthy controls. During acute disease, 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed and Generalized Estimating Equations (GEE) was used to account for the intra-person correlations inherent to repeated measures and assess statistically significant differences at $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. During 3 and 8 months convalescence, only 1 sample from each patient was analysed and Kruskal-Wallis with Dunn's multiple comparisons test was used to assess statistically significant differences. (c-d) Spearman correlation for frequency of virus-specific cTfh versus (c) titers of plasma immunoglobulins against the spike and RBD, and versus (d) frequency of blood plasmablast during acute disease. For patients with longitudinal acute samples, data from the earliest sample was involved as representative in Spearman correlation analysis. (e) Bar charts show the median concentration of IL-21, IFN γ , IL-4, IL-17 cytokines in supernatants of SARS-CoV-2 spike and RBD protein stimulated PBMCs from COVID-19 patients with acute disease. Dotted lines show the median concentration of cytokines with 95% CI (grey area) in supernatants from SARS-CoV-2 spike and RBD protein stimulated PBMCs from healthy controls. 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed and Generalized Estimating Equations (GEE) was used to account for the intra-person correlations inherent to repeated measures and assess statistically significant differences. (f-g) Heatmap summarizing the interrelationship between characteristics of cTfh cells and (f) clinical parameters, and (g) levels of plasma cytokines/chemokines from COVID-19 patients with acute disease. 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed and repeated measures correlations were calculated.



cTfh isolated from severe COVID-19 patients with acute disease support B cells differentiation and antibody production more efficiently than that from mild COVID-19 patients. (a) Blood cTfh, non-cTfh, memory B and naïve B cells were isolated from four severe and mild COVID-19 patients with acute disease, as well as four healthy donors. cTfh or non-cTfh cells were cultured with autologous memory B cells for 6 days, or with autologous naïve B cells for 9 days respectively. (b) Representative example with gating strategy to identify (left) memory B cell and (right) naïve B cell differentiation. (c) Bar charts show the number of live B cells in (left) cTfh/non-cTfh co-cultured with memory B cells and (right) cTfh/non-cTfh co-cultured with naïve B cells. (d) Bar charts show the frequency of plasmablast in cTfh-memory/naïve B cell co-cultured. (e-f) Bar charts show the concentration of (e) IgA and (f) IgG in supernatant from cTfh/non-cTfh co-cultured with (left) memory B cells and (right) naïve B cells. (g) Bar charts show the concentration of IL-21 in supernatant from cTfh/non-cTfh co-cultured with (left) memory B cells and (right) naïve B cells. In e-g ND means not detectable. One-Way ANOVA was used to consider statistically significant at $p < 0.05$. ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.



Delayed emergence of activated and virus-specific cTfh cells correlated with delayed emergence of high avidity and neutralization plasma antibodies in severe COVID-19 patients compared to mild and moderate patients. (a-c) Bar charts show the frequency of (a) cTfh cells, (b) activated cTfh cells and (c) SARS-CoV-2 spike and RBD-specific cTfh cells with mean in COVID-19 patients with acute disease according to weeks after symptom onset. Bar charts show the frequency of (d) SARS-CoV-2 spike and RBD-specific, (e) activated CXCR5-memory CD4 T cells (non-cTfh cells) with mean in COVID-19 patients with acute disease according to weeks after symptom onset. (f) Bar charts show the avidity index of plasma IgG during acute disease against SARS-CoV-2 spike across peak disease severity over weeks after symptom onset with mean. (g) Spearman correlation for frequency of activated and virus-specific cTfh during acute disease versus avidity index of plasma IgG during acute disease. (a-g) 9, 22 and 33 individual samples from 9 mild, 14 moderate and 18 severe patients respectively were analysed. (h, j) Bar charts show the (h) neutralization IC100 and (j) anti-spike IgG neutralization potency index of COVID-19 patient plasma samples across peak disease severity over weeks after symptom onset. (i) Spearman correlation for frequency of activated and virus-specific cTfh during acute disease versus plasma neutralization IC100 during acute disease. (h-j) 9, 22 and 31 individual samples from 9 mild, 14 moderate and 17 severe patients respectively were analysed. Dots are individual samples color-coded according to peak disease severity. Dotted lines show the mean frequency with 95% CI (grey area) of healthy controls. X axis shows number of patients in each bar. Dots from same patient are linked with line in each bar. Time-period specific differences between groups in were calculated using by using time-period specific subsets of the data. The graphical presentations of the different outcomes were based on a GEE model with time modelled using a restricted cubic spline with knots at 0, 14, 21, 28 and 53 days. Statistically significant differences were assessed at $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. (g, i) Only 1 individual sample from each patient was analysed for Spearman correlation during acute disease. For patients with longitudinal acute samples, data from the earliest sample was involved as representative in Spearman correlation analysis.

Table 1. Demographic and clinical data of COVID-19 patients and healthy controls

| | COVID-19 | Healthy Controls | Significance ^A |
|---|------------|------------------|---------------------------|
| Number of Individuals | 49 | 20 | |
| Age in year, median (range) | 55 (26-77) | 53 (24-81) | ns |
| Male, n (%) | 33 (67) | 14 (70) | ns |
| Female, n (%) | 16 (33) | 6 (30) | |
| Comorbidities ^B | | | |
| CCI ^C , median (IQR) | 1 (3) | - | NA |
| BMI, median (IQR) | 28.1 (5.4) | NA | NA |
| Hypertension, n (%) | 12 (24.5) | 0 | P < 0.001 |
| Diabetes, n (%) | 13 (26.8) | 0 | P < 0.001 |
| Current smoker, n (%) | 2 (4.1) | 0 | ns |
| Laboratory Analyses ^{B,D} | | | |
| CRP ^E , median (IQR) | 155 (174) | 1 (1) | P < 0.001 |
| WBC ^F , median (IQR) | 7.6 (4.9) | 6.8 (1.8) | ns |
| Neutrophils ^F , median (IQR) | 6.2 (3.9) | 3.8 (1.3) | P < 0.001 |
| Lymphocytes ^F , median (IQR) | 0.8 (0.5) | 1.9 (0.7) | P < 0.0001 |
| NLR ^G , median (IQR) | 7.4 (7.6) | 1.8 (1.3) | P < 0.0001 |

^A Mann-Whitney U and Fisher's exact test were performed to determine statistical significance. ^B Comorbidities and laboratory analyses data were available from 41 patients. ^C CCI = Charlson Comorbidity Index. ^D Peak values: CRP. Nadir values: lymphocyte count. WBC and neutrophil counts at the time point of the lowest lymphocyte count. ^E mg/L. ^F 10⁹ cells/L. ^G NLR = Neutrophil/lymphocyte ratio.

Normal range: CRP < 3 mg/L, WBC 3.5 × 10⁹/L to 8.8 × 10⁹/L, lymphocytes 1.1 × 10⁹/L to 3.5 × 10⁹/L, neutrophils 1.6 × 10⁹/L to 5.9 × 10⁹/L, monocytes 0.2 × 10⁹/L to 0.8 × 10⁹/L.

Table 2. Demographic and clinical data of COVID-19 patients across peak disease severity

| Peak Disease Severity | Mild | Moderate | Severe | Significance ^A |
|---|------------------|------------|------------|---------------------------|
| n (%) | 13 (27) | 14 (28) | 22 (45) | |
| Age in year, median (range) | 51 (29-72) | 54 (26-76) | 62 (32-77) | P < 0.05 |
| Male, n (%) | 5 (38) | 9 (64) | 19 (86) | P < 0.01 |
| Female, n (%) | 8 (62) | 5 (36) | 3 (14) | |
| Onset to admission ^{B,D} , median (IQR) | n/a ^C | 10 (5) | 11 (8) | ns |
| Cortisone during sample period, n (%) | 0 (0) | 2 (14) | 1 (5) | ns |
| Length of stay ^{B,D} , median (IQR) | n/a ^C | 13 (6) | 21 (12) | P < 0.01 |
| Comorbidities ^E | | | | |
| CCI ^F , median (IQR) | 0 (2) | 1 (3) | 2 (2) | ns |
| BMI, median(IQR) | 25.1 (6.0) | 30.1 (7.0) | 29.1 (4.7) | P < 0.01 |
| Hypertension, n (%) | 1 (9) | 5 (38) | 7 (35) | ns |
| Diabetes, n (%) | 2 (18) | 6 (38) | 6 (30) | ns |
| Current smoker, n (%) | 0 (0) | 2 (13) | 0 (0) | ns |
| Laboratory Analyses in Acute Disease ^{E,G} | | | | |
| CRP ^H , median(IQR) | 1 (60) | 163 (145) | 239 (173) | P < 0.0001 |
| WBC ^I , median (IQR) | 4.1 (1.0) | 7.8 (2.8) | 9.4 (4.3) | P < 0.001 |
| Neutrophils ^I , median (IQR) | 2.0 (1.1) | 6.3 (2.7) | 7.1 (4.4) | P < 0.0001 |
| Lymphocytes ^I , median (IQR) | 1.5 (0.4) | 0.9 (0.4) | 0.7 (0.3) | P < 0.01 |
| NLR ^J , median (IQR) | 1.2 (0.2) | 6.6 (5.9) | 10.0 (9.4) | P < 0.0001 |
| Ct value, median(IQR) | 27.5 (9.4) | 26.3 (7.4) | 25.8 (9.1) | ns |
| Laboratory Analyses in 3-month Convalescence ^{E,G} | | | | |
| CRP ^H , median (IQR) | 1 (1) | 2 (2) | 2 (5) | P ≤ 0.05 |
| WBC ^I , median (IQR) | 4.8 (2.4) | 6.5 (1.9) | 6.6 (2.8) | ns |
| Neutrophils ^I , median (IQR) | 2.6 (1.4) | 4.0 (1.5) | 3.5 (1.6) | ns |
| Lymphocytes ^I , median (IQR) | 1.7 (0.6) | 2.0 (1.0) | 1.9 (1.0) | ns |
| NLR ^J , median (IQR) | 1.6 (0.5) | 1.7 (1.4) | 1.8 (0.9) | ns |
| Laboratory Analyses in 8-month Convalescence ^{E,G} | | | | |
| CRP ^H , median (IQR) | 1 (1) | 1 (2) | 2 (2) | ns |
| WBC ^I , median (IQR) | 5.3 (1.1) | 7.1 (3.4) | 5.4 (3.0) | ns |
| Neutrophils ^I , median (IQR) | 3.0 (1.2) | 3.8 (1.0) | 3.2 (1.9) | ns |
| Lymphocytes ^I , median (IQR) | 1.9 (0.7) | 2.1 (0.9) | 1.8 (1.2) | ns |
| NLR ^J , median (IQR) | 1.6 (0.6) | 1.8 (0.7) | 1.5 (1.0) | ns |

^A Kruskal-Wallis' and Fisher's exact tests were performed to determine statistical significance. ^B Days. ^C Two patients with mild disease admitted: onset to admission 14 and 8 days, length of stay 2 and 7 days respectively. ^D Mann-Whitney U was performed to determine statistical significance. ^E Comorbidities and laboratory analyses data were available from 41 patients. ^F CCI = Charlson Comorbidity Index. ^G Peak values: CRP. Nadir values: lymphocyte count, Ct value. WBC and neutrophil counts at the time point of the lowest lymphocyte count. ^H mg/L. ^I 10⁹ cells/L. ^J NLR = Neutrophil/lymphocyte ratio.

Normal range: CRP < 3 mg/L, WBC 3.5 × 10⁹/L to 8.8 × 10⁹/L, lymphocytes 1.1 × 10⁹/L to 3.5 × 10⁹/L, neutrophils 1.6 × 10⁹/L to 5.9 × 10⁹/L, monocytes 0.2 × 10⁹/L to 0.8 × 10⁹/L.

Table 3. Demographic and clinical data of COVID-19 patients sampled less than two weeks after symptom onset

| Peak Disease Severity | Mild | Moderate | Severe | Significance ^A |
|---------------------------------|------------|------------|------------|---------------------------|
| n (%) | 7 (33) | 9 (43) | 5 (24) | |
| Age in year, median (range) | 38 (29-72) | 52 (41-67) | 49 (32-62) | ns |
| Male, n (%) | 2 (28) | 5 (56) | 4 (90) | ns |
| Female, n (%) | 5 (72) | 4 (44) | 1 (10) | |
| Comorbidities | | | | |
| CCI ^B , median (IQR) | 0 (0) | 1 (3) | 1 (2) | ns |
| BMI, median (IQR) | 24.5 (4.9) | 30.4 (4.4) | 32.8 (6.0) | P < 0.05 |
| Hypertension, n (%) | 0 (0) | 2 (22) | 0 (0) | ns |
| Diabetes, n (%) | 1 (14) | 3 (33) | 1 (20) | ns |
| Current smoker, n (%) | 0 (0) | 2 (22) | 0 (0) | ns |

^A Kruskal-Wallis' and Fisher's exact tests were performed to determine statistical significance.

^B CCI = Charlson Comorbidity Index.